Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a Healthcare company (Biotechnology) with a market capitalization of $4.6B. The Maz Rating grades it against the other companies in its sector.
Adaptive Biotechnologies Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $28.49, Adaptive Biotechnologies Corporation trades at 15.5x sales and 25.9x book value. Over the last twelve months it generated about $298M of revenue and a net loss of $73M. It runs a gross margin of 74.0%, an operating margin of -16.2% and a net margin of -23.7%. It shows return on equity of -37.4%, return on invested capital of -8.1% and a free cash flow yield of -0.2%. On the balance sheet: a debt-to-equity ratio of 2.32 and a current ratio of 3.97. Over the past 52 weeks the share price ranged from $12.00 to $32.21, with a beta of 2.15.
Adaptive Biotechnologies Corporation does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 11 Buy, 4 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Adaptive Biotechnologies Corporation (ADPT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 7.97% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.51% / 30% · Interest income / Revenue 4.49% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 7.97% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.10% / 33% · Receivables / Mkt Cap (36m) 1.58% / 49% · Interest income / Revenue 4.49% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 7.97% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.10% / 33.33% · Receivables / Mkt Cap (24m) 1.58% / 33.33% · Interest income / Revenue 4.49% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 43.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 46.5% / 33.33% · Receivables / Avg Assets (4Q) 9.17% / 33.33% · Interest income / Revenue 4.49% / 5% | Fail |
| FTSE | Debt / Total Assets 49.1% / 33.33% · (Cash+ST Inv) / Total Assets 43.8% / 33.33% · (Cash+Recv) / Total Assets 53.5% / 33.33% · Interest income / Revenue 4.49% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Adaptive Biotechnologies Corporation (ADPT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Adaptive Biotechnologies Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.49% of each dividend: Adaptive Biotechnologies Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.